Introduction
============

Epigenetics is defined as a heritable change in phenotype without a change to the underlying DNA sequence. Epigenetics plays a major role in the regulation of genomic structure, and through this can modulate gene expression. A length of up to two meters of DNA is contained within the nucleus of a single cell and, to ensure that the genome remains functional and accessible, is kept in a highly structured state. The DNA is coiled into 146-base pair (bp) loop structures termed nucleosomes that contain a protein octamer composed of two copies of each of the histones H2A, H2B, H3, and H4. Post-translational modifications of the histone proteins or their substitution with histone variants alter the structure of chromatin, which then can become tightly packed and transcriptionally inactive, termed heterochromatin, or open and transcriptionally active, termed euchromatin \[[@B1],[@B2]\]. Modifications occur primarily at the N-terminal tails of the histone proteins and include, but are not limited to, sumoylation, ubiquitination, phosphorylation, methylation, and acetylation. The best-studied modifications are histone methylation and acetylation, which have particular relevance to carcinogenesis. Tri-methylation of histone H3 lysine 27 (H3K27me3) is a repressive histone modification regulated by the polycomb group (PcG) family of proteins. The histone methyltransferase *EZH2*(enhancer of Zeste homologue 2) is the catalytic subunit of the polycomb repressive complex 2 (PRC2), is commonly aberrantly expressed in cancer, and has been associated with aggressive disease \[[@B3]\]. Control of histone acetylation is carried out by histone de-acetylases (HDACs) and histone acetyltransferases. Inhibition of HDACs has been shown to induce differentiation in cancer \[[@B4]\] and shows promise as a potential epigenetic therapy for cancer treatment (reviewed briefly in \[[@B5]\]).

In addition to histone modifications, the transcriptional state of a gene can be modulated through the covalent modification of the DNA strand itself, namely by the addition of methyl groups to cytosine residues found in cytosine followed by guanosine dinucleotide pairs (CpG). CpG dinucleotides are statistically under-represented within the genome because of a relatively high mutational rate \[[@B6],[@B7]\]. However, CpG dinucleotides are commonly distributed in high-density clusters - termed CpG islands - that are often associated with gene promoter regions \[[@B8],[@B9]\]. Methylation at promoter CpG islands leads to transcriptional repression and is associated with silencing chromatin marks. Inversely, methylation of gene body CpGs is associated with increased expression and active chromatin marks \[[@B10],[@B11]\]. Methylation of the DNA is performed predominantly by the core DNA methyltransferases (DNMTs) *DNMT1*, *DNMT3A*, and *DNMT3B*, which play specific roles in the control of DNA methylation \[[@B12]\]. *DNMT1*is responsible for the maintenance of DNA methylation after DNA replication. *DNMT1*methylates cytosines on the nascent DNA strand and has a preference for hemi-methylated CpG sites. *DNMT3A*and *DNMT3B*perform *de novo*methylation and methylate fully unmethylated CpG sites. *DNMT3A*also interacts with the gene body chromatin modification H3K36me3 and has been implicated as being responsible for gene body methylation \[[@B13]\]. The regulation of gene expression by DNA methylation has particularly prominent roles in cellular differentiation and development. It is well established that embryonic stem cells (ESCs) and fully differentiated cells display widely different genomic methylation patterns \[[@B14]\]. Increasing methylation of pluripotency genes pushes cells toward a more differentiated state, a process that has been well characterized in breast epithelium. ESCs and breast epithelial progenitor cells display similar DNA methylation profiles across differentiation- and pluripotency-associated genes (Figure [1](#F1){ref-type="fig"}) \[[@B15]\]. These genes become hypermethylated during differentiation and lineage commitment leading to the acquisition of cell type-specific gene expression profiles \[[@B15]\]. These cells also display cell type-specific chromatin modification profiles, particularly in polycomb-regulated H3K27me3 marked genes \[[@B16]\]. In summary, both histone modifications and DNA methylation have been implicated in a wide variety of biological processes such as differentiation, genomic stability, and carcinogenesis.

![**Progression of the breast cell epigenome from progenitor to malignancy**. During progression from progenitor cell to differentiated epithelium, cells exhibit an increasing level of DNA methylation as differentiation options are restricted. During cancer development, much of this genomic methylation is lost, with the exception of a small subset of genomic loci that exhibit DNA hypermethylation. Genomic hypomethylation is associated with increased genomic instability. The methylome of malignant lesions is remarkably similar between early lesions like ductal carcinoma *in situ*and later lesions like invasive ductal carcinoma.](bcr3237-1){#F1}

Traditionally, the study of epigenetic modifications was performed at one or a few genomic loci at a time. Recent improvements in technology have led to high-throughput methods that allow the interrogation of many or all genes in the genome simultaneously. The combination of methylated DNA enrichment or chromatin immunoprecipitation with microarray or next-generation sequencing (ChIP-chip and ChIP-seq, respectively) has resulted in a drastic increase in the number of genomic loci that can be assessed for epigenetic information simultaneously. These technological improvements have seen a great increase in the amount of genome-wide epigenetic data being produced and have given insight into the role of epigenetics in development, embryogenesis, and complex disease. This is especially pronounced within the field of cancer research. This review aims to integrate some of the recent findings of epigenomic research in cancer and will cover in detail an under-used but powerful model of early breast carcinogenesis: human mammary epithelial cells (HMECs) (reviewed in \[[@B17]\]).

Epigenetics and cancer
======================

Epigenetic dysregulation has long been identified as contributing to the cancer phenotype. Global hypomethylation of the genome is considered a hallmark of cancer and was one of the earliest epigenetic traits identified in cancer cells \[[@B18]\]. Hypomethylation contributes to carcinogenesis in a variety of ways and, in mice, has been demonstrated to trigger the initiation of cancer \[[@B19]\]. DNA methylation is crucial to the inactivation of transposable genetic elements, and during carcinogenesis genomic demethylation can lead to the reactivation of these elements \[[@B20]\]. Unwanted transposition results in genomic instability, which deals further damage to the cancer genome and contributes to phenotype. Hypomethylation at the pericentric repeat regions also leads to an increase in instability without the activation of transposable elements. Instead, hypomethylation at the pericentric regions results in miss-segregation of chromosomes during cell division and leads to aneuploidy \[[@B21],[@B22]\]. Increased genomic instability results in a higher instance of genomic rearrangements and leads to the formation of gene fusions and aberrant gene regulation. Additionally, induced hypomethylation of the genome of ESCs can block the capacity for differentiation \[[@B23]\], implicating this process in the loss of differentiation and increased capacity for self-renewal witnessed in cancer.

Hypermethylation of gene promoters adds to the cancer phenotype
===============================================================

While the cancer genome displays an overall decrease in the level of methylation compared with normal cells, CpG island-associated promoters, including tumor suppressor gene promoters, are commonly hypermethylated in cancer. Among the best-described methylation events in breast cancer are hypermethylations of p16^ink4a^(*CDKN2A*), *RASSF1A*, *CCND2*, *APC*, *NES1*(*KLK10*), *RARB*, and *HIN-1*(*SCGD3A1*) \[[@B24]-[@B32]\]. Several of these genes are also putative tumor suppressors, and aberrant promoter methylation is associated with gene repression and evasion of apoptosis or deregulation of the cell cycle. A recent study by Helman and colleagues \[[@B33]\] (2011) also demonstrated that hypermethylation of differentiation and developmental genes is crucial to lung carcinogenesis. Interestingly, several of these genes, such as *PAX6*, *WT1*, *PROX1*, *HOXB13*, *HOXA1*, and *HOXA9*, are also reported to be hypermethylated in breast cancer \[[@B34]-[@B38]\], suggesting that aberrant methylation and silencing of these gene sets may be as important to carcinogenesis as the aberrant silencing of tumor suppressors. Additionally, studies have demonstrated that the intrinsic molecular subtypes of breast cancer \[[@B39]\] exhibit different genomic methylation profiles \[[@B40],[@B41]\]. Basal-like cancers, in particular, can be identified on the basis of their methylation level of a set of polycomb-regulated genes \[[@B40],[@B41]\]. Given the relationship between the subtypes of breast cancer and patient outcome \[[@B39]\], understanding the relationship between DNA methylation and subtype may be of clinical relevance to breast cancer diagnosis or prognosis or both.

DNA methylation is an early event in breast carcinogenesis
==========================================================

Several studies have sought to elucidate the timing of methylation changes during breast carcinogenesis by comparing normal, pre-malignant lesions, and malignant breast tissue. In one such study, Park and colleagues \[[@B34]\] (2011) compared the methylation profile of 15 promoter-associated CpG islands in normal breast (NB) with the pre-malignant lesions atypical ductal hyperplasia (ADH) and flat epithelial atypia (FEA) and the malignant lesions ductal carcinoma *in situ*(DCIS) and invasive ductal carcinoma (IDC). The results showed that a significant increase in DNA methylation levels of promoter CpG islands occurred between NB and ADH/FEA. Additionally, there was a second significant gain in methylation between ADH/FEA and the malignant lesions, but no significant change in methylation profiles between DCIS and IDC, indicating that methylation is an early event in breast carcinogenesis (Figure [1](#F1){ref-type="fig"}). The data also agree with earlier reports of significant CpG island hypermethylation of estrogen receptor-alpha (*ESR1*), E-cadherin, *RASSF1A*, *CCND2*, p16, 14-3-3-σ, and SFRP1 in both DCIS and IDC \[[@B42]-[@B46]\]. Lehmann and colleagues \[[@B43]\] (2002) also assessed the methylation of *CCDN2*across grade-1 to -3 DCIS and found that *CCDN2*displayed higher methylation in higher-grade DCIS. This suggests that DNA hypermethylation occurs early in breast carcinogenesis and is associated with higher grade.

DNA methylation as a marker for diagnosis and prognosis
=======================================================

The tumor-specific nature of differentially methylated regions (DMRs) provides potential clinical biomarkers for cancer detection. Additionally, the presence of tumor-derived free DNA in the blood of patients with cancer \[[@B47],[@B48]\] promises the development of simple and non-invasive tests for cancer diagnosis/prognosis. Many studies have associated promoter methylation (and subsequent gene silencing) in breast cancer with various clinic-pathological parameters. For example, hypermethylation at the promoters of putative tumor suppressors *LATS1*and *LATS2*was found to be associated with large tumor size, probability of metastasis, and negative estrogen/progesterone receptor status \[[@B44]\]. Hypermethylation of the repressor of wnt signaling, *SFRP1*, was associated with reduced overall survival \[[@B46]\], and hypermethylation of *APC*, *CDH1*, or *CTNNB1*can distinguish cancer from normal tissue but is not associated with clinical outcome \[[@B49]\]. Table [1](#T1){ref-type="table"} provides a summary of all genes currently reported to have an association between promoter DNA hypermethylation or DNA hypomethylation (or both) and prognosis in breast cancer \[[@B36],[@B46],[@B50]-[@B74]\]. In this table, we have highlighted the cohort size and the method used to detect DNA methylation as each method has different sensitivity and specificity and may not necessarily be directly comparable. It is interesting to note that, despite the global hypomethylation of the cancer genome, only two studies found statistically significant associations between gene promoter hypomethylation and outcome of patients with breast cancer. However, hypomethylation of repetitive elements in the breast cancer genome has been associated with clinical outcome. Hypomethylation of long interspersed element 1 (LINE1) in a breast cancer cohort (379 primary ductal breast tumors, assayed by MethyLight) was associated with decreased overall survival (hazard ratio (HR) = 2.19, *P*= 0.014), decreased disease-free survival (HR = 2.05, *P*= 0.016), and increased distant recurrence (HR = 2.83, *P*= 0.001) in a multivariate analysis \[[@B75]\]. The relative lack of promoter hypomethylation in the cancer genome relative to the higher frequency of promoter hypermethylation may indicate different regulatory mechanisms and roles in carcinogenesis (reviewed in \[[@B76],[@B77]\]).

###### 

A summary of aberrant DNA methylation associated with outcome in breast cancer

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene symbol                  Tissue type   Hyper/Hypo   Cohort size                                                                                                       Detection method   Association with prognosis                                                              *P*value      Hazard ratio^a^   Reference
  ---------------------------- ------------- ------------ ----------------------------------------------------------------------------------------------------------------- ------------------ --------------------------------------------------------------------------------------- ------------- ----------------- ------------
  *ACADL*                      NR            Hyper        59 ductal carcinomas, 24 matched normal                                                                           IA/CoBRA           Reduced relapse-free survival                                                           0.0001                          \[[@B50]\]

  *BMP4*                       FF            Hyper        241 patients with breast cancer                                                                                   MethyLight         Reduced time to distant metastasis                                                      0.0002                          \[[@B51]\]

  *BRCA1*                      FFPE          Hyper        536 tumors (Chinese patients)                                                                                     MSP                Reduced disease-free survival                                                           0.045         1.45              \[[@B52]\]

                                                                                                                                                                                               Reduced disease-specific survival                                                       0.038         1.56              

                               FF            Hyper        241 patients with breast cancer                                                                                   MethyLight         Reduced time to distant metastasis                                                      0.018                           \[[@B51]\]

                               Serum         Hyper        105 tumors, 20 unmatched normal                                                                                   MSP                Poor prognosis                                                                          0.002         6.4               \[[@B53]\]

                               FF            Hyper        82 primary breast cancer tissues (Tunisian cohort)                                                                MSP                Five-year survival                                                                      0.016                           \[[@B54]\]

  *BRCA1*or *P16*or both       Serum         Hyper        105 tumors, 20 unmatched normal                                                                                   MSP                Poor prognosis                                                                          0.002         10.7              \[[@B53]\]

  *C20ORF55*                   FF            Hyper        241 patients with breast cancer                                                                                   MethyLight         Reduced time to distant metastasis                                                      0.001                           \[[@B51]\]

  *CDO1*                       FF            Hyper        163 tumors, 64 with distant metastasis                                                                            Q-BSSeq            Reduced time to distant metastasis                                                      \<0.0128      \>3.5             \[[@B55]\]

                                                                                                                                                                                               Reduced metastasis-free survival                                                        \<0.0034                        

  *CIDEB*                      FF            Hyper        110 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.002         4.02              \[[@B56]\]

  *CST6*                       FFPE          Hyper        93 carcinomas, 10 carcinomas with adjacent normal, 10 fibroadenomas, and 11 normal                                MSP                Reduced disease-free interval Reduced overall survival                                  0.004 0.001                     \[[@B57]\]

                                                                                                                                                                                               Reduced disease-free interval                                                           0.027         3.48              

                                                                                                                                                                                               Reduced overall survival                                                                0.004         9.19              

  *DKK3*                       FF            Hyper        153 primary invasive cancers, 19 normal                                                                           MSP                Reduced overall survival                                                                0.011         14.4              \[[@B58]\]

                                                                                                                                                                                               Reduced disease-free survival                                                           0.047         2.5               

  *ELK1*                       FF            Hyper        130 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.005         3.53              \[[@B56]\]

  *ESR2 (ER-B)*                FF            Hyper        55 cancers                                                                                                        MSP                Increased incidence of relapse                                                          0.016                           \[[@B59]\]

  *FGF12*                      FF            Hyper        113 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.004         3.31              \[[@B56]\]

  *FGF4*                       FF            Hyper        241 patients with breast cancer                                                                                   MethyLight         Reduced time to distant metastasis                                                      0.029                           \[[@B51]\]

  *FOXH1*                      FF            Hyper        129 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.00007       5.09              \[[@B56]\]

  *FOXL2*                      FF            Hyper        241 patients with breast cancer                                                                                   MethyLight         Reduced time to distant metastasis                                                      0.02                            \[[@B51]\]

  *GSTP1*                      FF            Hyper        176 invasive tumors (Japanese cohort)                                                                             MSP                Reduced relapse-free survival                                                           \<0.01                          \[[@B60]\]

                                                                                                                                                                                               Poor prognosis                                                                          \<0.05        2.77              

                                                                                                                                                                                               Poor prognosis                                                                          \<0.01        7.13              

                               FFPE          Hyper        974 primary *in situ*or invasive breast cancers                                                                   MethyLight         Increased breast cancer-specific mortality                                              NR            1.71              \[[@B61]\]

                               FFPE          Hyper        50 breast tumors                                                                                                  MSP                High Nottingham Prognostic Index                                                        0.0017                          \[[@B62]\]

  *HOXB13*                     FF            Hyper        57 ER-α+ tumors                                                                                                   QM-PCR             Reduced disease-free survival                                                           0.029         3.25              \[[@B36]\]

  *ID4*                        FF            Hyper        171 tumors and match normal                                                                                       MSP                Reduced recurrence-free survival                                                        0.036                           \[[@B63]\]

  *ITIH5*                      FF            Hyper        109 tumors                                                                                                        MSP                Reduced overall survival                                                                0.008                           \[[@B64]\]

  *ITR*                        NR            Hyper        59 ductal carcinomas, 24 matched normal                                                                           IA/CoBRA           Reduced relapse-free survival                                                           0.0041                          \[[@B50]\]

  *KLK10*                      FFPE          Hyper        128 breast carcinomas, 10 breast carcinomas with paired adjacent normal, 10 breast fibroadenomas, and 11 normal   MSP                Reduced disease-free interval Reduced overall survival Increased incidence of relapse   0.0025\       /\                \[[@B65]\]
                                                                                                                                                                                                                                                                                       0.003\        /\                
                                                                                                                                                                                                                                                                                       0.026         3.49              

  *LHX5*                       FF            Hyper        125 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.032         2.94              \[[@B56]\]

  *MLH1*                       FF            Hyper        86 primary breast cancer tissues (Tunisian cohort)                                                                MSP                Reduced overall survival                                                                0.015                           \[[@B54]\]

  *NR2E1*                      FF            Hyper        241 patients with breast cancer                                                                                   MethyLight         Reduced time to distant metastasis                                                      0.02                            \[[@B51]\]

  *OLIG2*                      FF            Hyper        115 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.023         2.56              \[[@B56]\]

  *ONECUT1*                    FF            Hyper        128 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.023         2.8               \[[@B56]\]

  *P16*                        Serum         Hyper        105 tumors, 20 unmatched normal                                                                                   MSP                Poor prognosis                                                                          0.001         5.5               \[[@B53]\]

  *PITX2*                      FFPE          Hyper        427 invasive cancers                                                                                              QM-PCR             Reduced time to distant metastasis                                                      0.004         2.75              \[[@B66]\]

                                                                                                                                                                                               Reduced time to distant metastasis                                                      0.013         2.35              

                                                                                                                                                                                               Reduced metastasis-free survival                                                        0.032         2.69              

                               FF            Hyper        241 patients with breast cancer                                                                                   MethyLight         High risk of distant recurrence                                                         0.026                           \[[@B51]\]

                                                                                                                                                                                               Reduced time to distant metastasis                                                      \<0.001                         

                                                                                                                                                                                               Reduced disease-free survival                                                           0.0084                          

                                                                                                                                                                                               Reduced overall survival                                                                0.0003                          

                               FF            Hyper        236 node-negative tumors                                                                                          Array/QM-PCR       Reduced metastasis-free survival                                                        \<0.00045     \>2.1             \[[@B67]\]

                               FF            Hyper        416 tumors                                                                                                        QM-PCR             Reduced time to distant metastasis                                                      \<0.01        1.71              \[[@B68]\]

                                                                                                                                                                                               Reduced overall survival                                                                \<0.01        1.71              

                                                                                                                                                                                               Reduced metastasis-free survival                                                        \<0.01        1.74              

                                                                                                                                                                                               Reduced overall survival                                                                0.02          1.46              

  *PITX2/BMP4/c20orf55/fgf5*   FF            Hyper        241 patients with breast cancer                                                                                   MethyLight         Increased risk of distant recurrence Increased risk of distant recurrence               \<0.01\                         \[[@B51]\]
                                                                                                                                                                                                                                                                                       \<0.01                          

  *RARB*                       FFPE          Hyper        967 primary *in situ*or invasive breast cancers                                                                   MethyLight         Increased breast cancer-specific mortality                                              NR            1.78              \[[@B61]\]

  *RASSF1A*                    FF            Hyper        80 tumors (Tunisian cohort)                                                                                       MSP                Poor survival                                                                           0.014                           \[[@B69]\]

                               FFPE          Hyper        93 carcinomas, 10 carcinomas with adjacent normal, 10 fibroadenomas, and 11 normal                                MSP                Increased incidence of relapse Reduced disease-free survival                            0.011\                          \[[@B70]\]
                                                                                                                                                                                                                                                                                       0.028                           

                               FNA           Hyper        237 patients with suspicious palpable lesions taken prior to surgery                                              QM-PCR             Reduced disease-free survival                                                           0.031         OR = 2.53         \[[@B71]\]

  *RECK*                       NR            Hyper        59 ductal carcinomas, 24 matched normal                                                                           IA/CoBRA           Reduced relapse-free survival                                                           0.0001                          \[[@B50]\]

  *SFRP1*                      FF            Hyper        131 tumors, 26 matched normal                                                                                     MSP                Reduced overall survival                                                                0.045                           \[[@B46]\]

  *SFRP2*                      NR            Hyper        59 ductal carcinomas, 24 matched normal                                                                           IA/CoBRA           Reduced relapse-free survival                                                           0.0001                          \[[@B50]\]

  *SFRP5*                      FF            Hyper        14 matched tumors and normal, 155 unmatched tumors                                                                MSP                Reduced overall survival                                                                0.049         4.55              \[[@B72]\]

  *SYNM*                       FF/FFPE       Hyper        195 breast cancers                                                                                                MSP                Reduced recurrence-free survival                                                        0.0282        2.94              \[[@B73]\]

  *TDGF1*                      FF            Hyper        109 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.0009        4.08              \[[@B56]\]

  *TLX3*                       FF            Hyper        241 patients with breast cancer                                                                                   MethyLight         Reduced time to distant metastasis                                                      0.008                           \[[@B51]\]

  *TUBB3*                      FF            Hyper        121 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.035         3.19              \[[@B56]\]

  *TWIST1*                     FFPE          Hyper        973 primary *in situ*or invasive breast cancers                                                                   MethyLight         Increased breast cancer-specific mortality                                              NR            1.67              \[[@B61]\]

  *UAP1L1*                     NR            Hyper        59 ductal carcinomas, 24 matched normal                                                                           IA/CoBRA           Reduced relapse-free survival                                                           0.0005                          \[[@B50]\]

  *UGT3A1*                     NR            Hyper        59 ductal carcinomas, 24 matched normal                                                                           IA/CoBRA           Reduced relapse-free survival                                                           0.0018                          \[[@B50]\]

  *UNC5A*                      FF            Hyper        111 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.027         2.74              \[[@B56]\]

  *ZNF1A1*                     FF            Hyper        241 patients with breast cancer                                                                                   MethyLight         Reduced time to distant metastasis                                                      0.044                           \[[@B51]\]

  *BTG1*                       FF            Hypo         124 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.013         2.65              \[[@B56]\]

  *GSC*                        FF            Hypo         132 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.002         3.69              \[[@B56]\]

  *HDAC4*                      FF            Hypo         117 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.016         2.62              \[[@B56]\]

  *JUN*                        FF            Hypo         131 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.025         2.44              \[[@B56]\]

  *MKI67 (KI-67)*              FF            Hypo         116 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.004         3.43              \[[@B56]\]

  *KIF2C*                      FF            Hypo         118 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.008         2.65              \[[@B56]\]

  *KLF4*                       FF            Hypo         114 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.009         2.63              \[[@B56]\]

  *KLF5*                       FF            Hypo         123 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.004         3.56              \[[@B56]\]

  *LHX2*                       FF            Hypo         126 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.028         2.32              \[[@B56]\]

  *MAPK12*                     FF            Hypo         120 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.001         3.51              \[[@B56]\]

  *MRD1*                       FF/serum      Hypo         100 invasive ductal carcinomas with matched normal and blood                                                      MSP                Reduced overall survival                                                                \<0.01                          \[[@B74]\]

  *ONECUT2*                    FF            Hypo         127 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.029         2.74              \[[@B56]\]

  *SPRY1*                      FF            Hypo         112 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.002         4.0               \[[@B56]\]

  *TOP1*                       FF            Hypo         108 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.0005        3.68              \[[@B56]\]

  *UBE2C*                      FF            Hypo         119 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.0009        3.57              \[[@B56]\]

  *VEGF*                       FF            Hypo         122 tumors, 11 normal (Indian cohort)                                                                             MOMA               Increased likelihood of relapse                                                         0.007         3.01              \[[@B56]\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Hazard ratio given where reported. FF, fresh frozen; FFPE, formalin-fixed paraffin-embedded; FNA, fine-needle aspirate; HR, hazard ratio; Hyper, hypermethylation; Hypo, hypomethylation; IA/CoBRA, infinium array/combined bisulfite restriction enzyme analysis; MOMA, methylation oligonucleotide analysis; MSP, methylation-specific polymerase chain reaction; NR, not reported; OR, odds ratio; Q-BSSeq, quantitative bisulphite sequencing; QM-PCR, quantitative methylation-specific polymerase chain reaction.

Histone modification profiles are altered in cancer
===================================================

Genome-wide studies of histone modification patterns have shown that specific histone modifications are associated with specific genomic functions and that these patterns are altered in cancer. For example, H3K4me3 (trimethylated histone 3 lysine 4) is a transcriptionally permissive histone modification associated with gene promoters \[[@B78]\] and can shed light on alternate promoter usage in carcinogenesis, whereas H3K27me3 is a repressive histone modification that marks large domains of the genome, including promoters, gene bodies, and inter-genic regions \[[@B79]\], and is important in development and differentiation. H3K27me3 marking is mediated by the polycomb repressive complex 2 (PRC2), and the repressive state is maintained by PRC1 \[[@B80]\]. The gene *EZH2*encodes the catalytic subunit of PRC2, and upregulation of *EZH2*in breast cancer has been associated with poor outcome \[[@B3]\]. Overexpression of *EZH2*results in the formation of an alternate complex, PRC4, which displays diering substrate specificity relative to PRC2 and is expressed predominantly in undifferentiated tissue or cancer cells \[[@B81]\].

The active H3K4me3 and repressive H3K27me3 marks can co-occur on a single molecule (as confirmed by ChIP-reChIP \[[@B82]\]) and is termed bivalent marking. Bivalent marking of gene promoters occurs frequently in ESCs and typically is associated with important regulatory genes (for example, regulators of differentiation, tumor suppressors, and cell cycle regulators) \[[@B82]\]. Bivalent marking is associated with a transcriptionally poised state and is proposed to prevent aberrant gene expression but allow for rapid activation during differentiation. Notably, genes displaying bivalent histone marks in ESCs are reported to have an increased propensity to become aberrantly hypermethylated in cancer, but the mechanism underpinning this is unknown \[[@B83]\].

Integrated analysis of genetic and epigenetic data is a powerful tool in genomics research. The histone modification H3K27Ac is a mark of active regulatory sequences (that is, enhancers and promoters) \[[@B84]\]. A recent study by Ernst and colleagues \[[@B85]\] (2011) used the H3K27Ac profile from a range of cells to identify cell type-specific regulatory elements. By integrating the chromatin profiles of multiple cell types with known non-coding disease-related single-nucleotide polymorphisms (SNPs), the authors found that non-coding SNPs often occurred within enhancer marked regions and disrupted transcription factor-binding sites. Therefore, it is important to consider both genetic and epigenetic aberrations in the investigation of carcinogenesis.

Human mammary epithelial cells as a model of breast carcinogenesis
==================================================================

Although the integration of chromatin modifications, genetic data, and DNA methylation is likely to deliver novel insights into the biology of cancer, it is still difficult to identify the earliest epigenetic events in carcinogenesis without appropriate model systems. Clinical tumor samples and cancer cell lines contain a cacophony of genetic and epigenetic aberrations that potentially obscure crucial cancer-driving changes from passengers and, moreover, cannot easily capture the progression of epigenomic change during carcinogenesis. The HMEC model system promises to recapitulate the earliest stages of carcinogenesis *in vitro*. HMEC lines are established by the culture of breast epithelial cells taken from healthy, disease-free individuals during breast reduction mammoplasty \[[@B86]\]. In culture, HMECs will enter a temporary period of senescence (termed stasis or selection) from which a subpopulation of cells known as vHMECs (also termed post-selection HMECs) can escape (Figure [2](#F2){ref-type="fig"}) \[[@B86]-[@B94]\]. However, vHMECs are not immortalized and eventually enter an inescapable period of growth arrest termed agonescence \[[@B89]\]. During agonescence, the vHMEC population is unable to expand but retains unexpectedly high cell viability \[[@B89]\]. Initially, vHMECs display a relatively stable genome; however, as the cells approach agonescence, they rapidly acquire serious genomic defects and exhibit a wildly altered karyotype typical of early cancer lesions \[[@B90]\].

![**Progression of the human mammary epithelial cell (HMEC) epigenome during growth**. HMECs undergo a brief initial period of exponential growth followed by a temporary growth arrest termed selection/stasis. A subpopulation of vHMECs is able to escape this senescence and exhibit a second, longer period of exponential growth before becoming permanently arrested at agonescence. Much like during cancer progression, HMECs undergo a stepwise change in DNA methylation levels at selection/stasis and then again following the forced oncogene-induced escape from agonescence. vHMEC, variant human mammary epithelial cell.](bcr3237-2){#F2}

Variant human mammary epithelial cells display cancer-associated epigenetic gene expression changes
===================================================================================================

Compared with HMECs, vHMECs display a significantly different expression program \[[@B88],[@B93],[@B95]-[@B102]\]. Among the earliest changes identified in vHMECs was the silencing of the tumor suppressor p16^ink4a^\[[@B96]\]. Silencing of p16^ink4a^occurs in all vHMEC populations and is associated with hypermethylation of the p16^ink4a^transcription start site (TSS) \[[@B87],[@B88],[@B96]\]. The gene encoding p16^ink4a^, *CDKN2A*, also encodes a second transcript called p14^arf^. The p14^arf^alternate TSS remains unmethylated in vHMECs, and transcription from this promoter is maintained. Notably, the p16^ink4a^locus is bivalently marked in HMECs, but in vHMECs H3K27me3 is lost in concert with a gain in promoter hypermethylation \[[@B103]\]. It is currently unclear whether vHMECs are a pre-existing subpopulation of normal HMECs or whether they arise *de novo*during selection in culture. Holst and colleagues \[[@B104]\] (2003) propose that vHMECs do exist prior to selection as the authors identified p16^ink4a^silenced and methylated p16^ink4a^cells in normal breast tissue, whereas Hinshelwood and colleagues \[[@B103]\] (2009) report that, in early vHMECs, p16^ink4a^methylation occurs only as the population of cells expand in culture and is a consequence of prior gene silencing. In addition to a change in p16^ink4a^expression, vHMECs display increased *Cox-2*expression \[[@B97]\]. *Cox-2*encodes a cyclo-oxygenase enzyme and is implicated in a wide variety of cancers, including breast cancer, to promote angiogenesis, invasion, and metastasis \[[@B105]\]. High *Cox-2*expression in vHMECs is also associated with an increased rate of growth and high motility, and silencing of *Cox-2*has been shown to reduce this malignant phenotype \[[@B97]\]. In addition to changes in individual gene expression, the transforming growth factor beta (TGFβ) pathway is consistently epigenetically silenced in vHMEC populations, and mutations in this pathway are commonly found in cancer. TGFβ pathway genes found to be silenced in vHMECs include *TGFB2*, the genes encoding the receptors *TGFBR1*and *TGFBR2*, and an activator of TGFβ, *THBS1*\[[@B101]\]. The TGFβ pathway is involved in regulation of the cell cycle, induction of apoptosis, and induction of differentiation. Detailed analysis demonstrated that genes in the TGFβ pathway are silenced without DNA hypermethylation and that gene silencing is associated with repressive chromatin remodelling and acquisition of H3K27me3 at gene promoters \[[@B101]\].

Interestingly, the PcG family of proteins is aberrantly regulated in vHMECs, specifi cally in the increased expression of *SUZ12*and *EZH2*\[[@B38]\]. *SUZ12*and *EZH2*are components of the PRC2 complex responsible for the methylation of histone 3 lysines 9 and 27 (H3K9me3 and H3K27me3). Increased expression of *EZH2*has been associated with poor outcome in breast cancer \[[@B3],[@B106]-[@B110]\]. As mentioned above, the PcG family of proteins plays important roles in the regulation of differentiation-related genes and may be involved in the recruitment of DNMTs \[[@B111]\]. In vHMECs, upregulation of *SUZ12*and *EZH2*appears to be linked to the silencing of p16^ink4a^\[[@B38]\]. Moreover, silencing of p16^ink4a^in HMECs by short hairpin RNA (shRNA) induced increased expression of *SUZ12*and *EZH2*. The deregulation of the PcG in vHMECs also results in the inappropriate hyper-methylation of specific gene promoters. Silencing of p16^ink4a^or increased *SUZ12*and *EZH2*expression in HMECs leads to increased methylation at the *HOXA9*promoter, mimicking its state in vHMECs \[[@B38]\]. Interestingly, hypermethylation was not seen in p16^ink4a^-silenced HMECs when *SUZ12*was inhibited by shRNA. Additionally, the *HOXA9*promoter was enriched for PcG proteins and DNMTs, suggesting a direct interaction. These results suggest that, in p16^ink4a^-silenced vHMECs, the PcG proteins and DNMTs interact to contribute to the pre-malignant breast cancer phenotype.

Variant human mammary epithelial cells proliferate rapidly despite elevated p53
===============================================================================

In addition to the many cancer-associated changes, vHMECs exhibit upregulation of tumor suppressors, including several key members of the p53 tumor suppressor pathway \[[@B95],[@B99],[@B102]\]. The p53 protein is a key tumor suppressor and regulates the cell cycle through the activation of cell cycle checkpoints or apoptosis or both. Activation of checkpoints is achieved through DNA binding by p53 and the activation of p53 response genes, such as p21, which mediates p53-induced G~1~cell cycle arrest \[[@B112]-[@B114]\]. Regulation of p53 is achieved through proteasomal degradation triggered by ubiquitinylation by the p53 regulator MDM2 \[[@B115]-[@B117]\]. In vHMECs, the p53 protein is stabilized, resulting in the upregulation of p21 \[[@B99],[@B102]\]. Multiple studies have demonstrated that vHMECs contain a wild-type, mutation-free p53 protein \[[@B95],[@B102]\] and that the p53 response to DNA damage remains intact \[[@B102]\]. However, vHMECs are able to expand faster than HMECs that have a low p53 expression. This increase in p53 stability has been linked to silencing of p16^ink4a^in two studies. Re-expression of p16^ink4a^in vHMECs results in reduced levels of p53 protein and p21 expression, whereas silencing of p16^ink4a^by shRNA in HMECs leads to p53/p21 activation \[[@B99],[@B102]\]. In vHMECs, p53 is stabilized despite the presence of high levels of MDM2 expression. An investigation into this phenomenon found that vHMECs express a truncated 60-kDa isoform of MDM2 that can bind p53 but does not induce its degradation \[[@B102]\]. A 60-kDa form of MDM2 has been reported in multiple cancer cell lines as a result of caspase cleavage \[[@B118],[@B119]\] that retains p53-binding capacity but lacks a C-terminal RING domain responsible for p53 ubiquitination \[[@B120]\]. This matches the properties of MDM2 observed in vHMECs. Silencing of p53 does not have an impact on the rate of growth of vHMECs \[[@B102]\]. Interestingly, silencing of p53 in an agonescent population results in loss of cell viability and widespread cell death \[[@B100]\], indicating that aberrations other than silencing of p53 are important in breast carcinogenesis.

Variant human mammary epithelial cells do not undergo oncogene-induced senescence
=================================================================================

Normal cells use several checkpoints to prevent malignant transformation and one such checkpoint is oncogene-induced senescence (OIS). OIS was identified in 1997 when overexpression of mutant Ras in normal rodent cells resulted in permanent growth arrest via p16^ink4a^and p53 \[[@B121]\]. Overexpression of Ras in vHMECs did not induce OIS, whereas Ras expression in isogenic HMECs did induce senescence \[[@B94]\]. This may not be surprising, as vHMECs do not express p16^ink4a^. However, further studies have demonstrated that oncogenic Ras can induce OIS in HMECs in a p16^ink4a^-independent manner \[[@B122]\]. This study found that, in p16^ink4a^/p53-negative HMECs, Ras-induced senescence was suppressed by the antagonism of TGFβ signaling. The lack of TGFβ pathway expression in vHMECs likely serves as an additional factor in their ability to avoid OIS. It is interesting to note that the expression of oncogenic Ras in vHMECs did not result in carcinogenic transformation. Neither an increased growth rate nor increased genomic instability was reported in vHMEC-Ras cells \[[@B94]\]. However, exposure of vHMEC-Ras to low levels of serum in the growth media during agonescence did result in spontaneous immortalization and the capacity to overcome this second proliferative barrier. Removal of the serum stimulus did not cause these cells to revert to their mortal state and indicates that this transformation is permanent. However, immortalized vHMEC-Ras cells were not tumorigenic when injected into mice. The ability of vHMECs to avoid OIS is further evidence that they represent a partially transformed, pre-malignant breast cancer cell type.

Variant human mammary epithelial cells exhibit an aberrant methylome
====================================================================

DNA hypermethylation at the p16^ink4a^promoter is well documented in vHMECs but does not represent the only change across the genome. A study into genome-wide DNA methylation by Novak and colleagues \[[@B123]\] (2009) used MeDIP-chip (methylated DNA immunoprecipitation followed by hybridization to microarrays) analysis on HMEC and vHMEC populations. vHMECs displayed a large number of DMRs (n = 191) when compared with their isogenic counterparts; notably, there was a significant overlap between vHMEC DMRs and methylation status in tumor samples. To confirm that the progressive nature of DNA methylation change was due specifically to transformation and not to a slow ongoing process induced by prolonged culture (Figure [2](#F2){ref-type="fig"}), Novak and colleagues (2009) tested several time-points during HMEC and vHMEC growth. HMECs from early and late passages displayed a similar and stable methylome, as did early- and late-passage vHMECs. Overall, the vHMEC methylome remained stable until immortalization, in which vHMECs undergo a further significant change, indicating a stepwise progression of DNA methylation during HMEC transformation, much like that reported in breast carcinogenesis (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). Notably, several of the genes reported as differentially methylated in vHMECs by Novak and colleagues (2009) also appear in the list of breast cancer prognostic marker genes (Table [2](#T2){ref-type="table"}).

###### 

Overlap of genes reported as hypermethylated in variant human mammary epithelial cells and as potential prognostic epigenetic markers in breast cancer

  Gene symbol     Methylation in vHMECs   *P*value of vHMECs   Methylation in immortal vHMECs   *P*value of immortal vHMECs   Methylation in cancer   Association in cancer
  --------------- ----------------------- -------------------- -------------------------------- ----------------------------- ----------------------- -------------------------------------------------------------------------
  *CDO1*          NA                      NA                   Hyper                            \<0.003                       Hyper                   Reduced time to distant metastasis and reduced metastasis-free survival
  *CIDEB*         Hyper                   0.001                Hyper                            \<0.000006                    Hyper                   Increased likelihood of relapse
  *ESR2 (ER-B)*   Hyper                   0.000002             Hyper                            \<0.000009                    Hyper                   Increased incidence of Relapse
  *FOXL2*         NA                      NA                   Hyper                            0.001                         Hyper                   Reduced time to distant metastasis
  *ID4*           Hyper                   \<0.004              Hyper                            \<0.004                       Hyper                   Reduced recurrence-free survival
  *NR2E1*         Hyper                   0.00001              Hyper                            \<0.000007                    Hyper                   Reduced time to distant metastasis
  *OLIG2*         Hyper                   \<0.01               Hyper                            \<0.008                       Hyper                   Increased likelihood of relapse
  *TLX3*          NA                      NA                   Hyper                            \<0.003                       Hyper/Hypo              Reduced time to distant metastasis
  *KIF2C*         Hyper                   0.004                NA                               NA                            Hypo                    Increased likelihood of relapse
  *TOP1*          NA                      NA                   Hypo                             0.01                          Hypo                    Increased likelihood of relapse
  *VEGF*          NA                      NA                   Hyper                            0.001                         Hypo                    Increased likelihood of relapse

Hyper, hypermethylation; Hypo, hypomethylation; NA, not available; vHMEC, variant human mammary epithelial cell.

Temporal changes in DNA methylation occur as variant human mammary epithelial cells escape senescence
=====================================================================================================

Despite the demonstrated stability of the vHMEC methylome \[[@B123]\], there is significant heterogeneity in methylation patterns across the p16 ^ink4a^promoter as determined by bisulphite sequencing. Some regions at this site appear to be protected from hypermethylation during gene silencing \[[@B103]\]. Until recently, whether methylation at the p16^ink4a^promoter was a cause or consequence of gene silencing was unknown. A study by Hinshelwood and colleagues \[[@B103]\] (2009) assessed hypermethylation of the p16^ink4a^promoter region of vHMECs in the first few population doublings following selection by using laser capture and found that p16^ink4a^was silenced prior to hypermethylation. The study also found that DNA hypermethylation was initiated at distinct foci or \'hot spots\' of DNA methylation that occurred at a regular pattern across the promoter, in accordance with the pattern of nucleosome occupancy (that is, approximately 147 bp unmethylated region followed by approximately 50 bp of hypermethylation). In a further investigation, chromatin from vHMECs was treated with the DNMT enzyme SssI *in vitro*. SssI can access only free DNA not bound to nucleosomes, and only the 50-bp linker region between nucleosomes is methylated during treatment. Bisulphite sequencing revealed foci of DNA methylation separated by a hypomethylated nucleosome-bound region that matched the methylation pattern seen *in vivo*. Hinshelwood and colleagues \[[@B103]\] (2009) proposed that silencing of p16^ink4a^is initiated in conjunction with the acquisition of repressive histone marks and that pre-existing hot spots of DNA methylation may serve as seeds of permanent silencing and the recruitment of DNMTs and other repressive complexes.

Future challenges for the human mammary epithelial cell system
==============================================================

Extension of this model system to include early malignancy should also be a focus of the breast cancer research field. To date, there is no system in which a study may follow the transformation from normal to pre-malignant to early malignant lesion (that is, DCIS) or beyond. Previous attempts to grow HMECs or vHMECs in mice have been unsuccessful without the introduction of oncogenes or humanizing the mouse mammary fat pad with human fibroblasts. When grown in humanized cleared mouse mammary fat pads, HMECs are able to generate normal breast ductal structures \[[@B124]\]. Additionally, the implantation of HMECs into mouse mammary fat pads humanized with fibroblasts transformed to abnormally express key growth factors resulted in the generation of structures similar to those seen in early breast malignancy \[[@B124]\]. These results demonstrate that the HMEC system is also a useful model for studies of the role of cancer/stroma interactions during carcinogenesis. The development of further model systems using HMECs and vHMECs that follow the natural progression of cancer growth *in vivo*will be invaluable to the understanding of breast cancer biology.

Conclusions
===========

This review has presented much evidence that demonstrates that epigenetic dysregulation is well established as a major contributor to cancer progression and phenotype. It can be clearly seen that changes in DNA methylation contribute to a wide variety of cancer-associated phenomena such as genomic instability, silencing of tumor suppressors, and inappropriate regulation of differentiation-associated pathways. Chromatin remodelling is also a powerful tool in the evolving cancer cell and contributes to deregulation of gene expression and the inappropriate targeting of DNA methylation observed in cancer. These epigenomic phenomena are being studied with ever more powerful, sensitive, and well-developed tools (for example, ChIP-seq), and use of next-generation genomics approaches demands the use of an equally powerful and sensitive model system. It should be clear that this role could be filled by the HMEC model system. HMECs and vHMECs are able to recreate *in vitro*the very earliest stages of carcinogenesis and exhibit a wide variety of cancer-associated expression, chromatin, and DNA methylation changes. Additionally, the HMEC system can be used to provide temporal information that cannot be obtained by using cancer cell lines or tissue samples, particularly in the very early stages of oncogenic transformation. In terms of both the generation of cancer biomarkers and the understanding of cancer biology, the HMEC system promises to deliver findings otherwise unavailable to cancer researchers.
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